Skip to main content
Erschienen in: International Urology and Nephrology 7/2019

22.05.2019 | Nephrology - Review

A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives

verfasst von: Cristiana Vlad, Alexandru Burlacu, Laura Florea, Bogdan Artene, Silvia Badarau, Andreea Covic, Carina Ureche, Dragos Scripcariu, Liliana Foia, Adrian Covic

Erschienen in: International Urology and Nephrology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nontraditional cardiovascular risk factors such as lipoprotein(a) (Lp(a)), the genetic polymorphisms of apolipoprotein(a), apolipoprotein E (ApoE), and apolipoprotein B (ApoB) increase the prevalence of atherosclerosis in end-stage renal disease (ESRD) through quantitative and qualitative alterations. Given the high burden of cardiovascular fatal events in ESRD, this review aims to gather studies depicting apolipoproteins’ changes in ESRD, to describe current evidence and to explore potential lipid-lowering therapies.

Methods

We searched the electronic database of PubMed, SCOPUS, EBSCO, and Cochrane CENTRAL for studies evaluating apolipoproteins in ESRD. Randomized controlled trials, observational studies (including case–control, prospective, or retrospective cohort), and reviews/meta-analysis were included if reference was made to apolipoproteins and cardiovascular consequences in ESRD.

Results

21 studies met the inclusion criteria. We found a significant correlation between Lp(a) plasma concentrations and atherosclerosis. Lp(a) levels were independent risk factors for atherothrombosis and cardiovascular mortality. LMW apo(a) phenotype proved to be the best predictor for coronary events in ESRD. Single nucleotide polymorphisms in ApoE gene affected the expression and function of the protein, increasing the risk of cardiovascular events. ApoB had a significant correlation with the value of carotid intima–media thickness and vascular stiffness.

Conclusions

The picture of “lipid milieu” in ESRD has not been clearly described. Novel studies show that specific apolipoproteins suffer modifications in uremic patients, being correlated with cardiovascular events. Probably in the next years, the treatment of dyslipidemia in ESRD will not merely target LDL or total cholesterol, but specific isoforms of apolipoproteins which seem to become the central part of the problem.
Literatur
1.
Zurück zum Zitat Parsons DS, Reaveley DA, Pavitt DV, Misra M, Brown EA (2003) Lipoprotein(a) levels in those with high molecular weight apo(a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol Dial Transpl 18(9):1848–1853CrossRef Parsons DS, Reaveley DA, Pavitt DV, Misra M, Brown EA (2003) Lipoprotein(a) levels in those with high molecular weight apo(a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol Dial Transpl 18(9):1848–1853CrossRef
3.
Zurück zum Zitat Nusair MB, Rajpurohit N, Alpert MA (2012) Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. Cardioren Med 2(2):117–124CrossRef Nusair MB, Rajpurohit N, Alpert MA (2012) Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. Cardioren Med 2(2):117–124CrossRef
5.
Zurück zum Zitat Shroff GR, Frederick PD, Herzog CA (2012) Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 163(3):399–406. https://doi.org/10.1016/j.ahj.2011.12.002 CrossRefPubMedPubMedCentral Shroff GR, Frederick PD, Herzog CA (2012) Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 163(3):399–406. https://​doi.​org/​10.​1016/​j.​ahj.​2011.​12.​002 CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kronenberg F, Utermann G, Dieplinger H (1996) Lipoprotein(a) in renal disease. Am J Kidney Dis 27(1):1–25CrossRef Kronenberg F, Utermann G, Dieplinger H (1996) Lipoprotein(a) in renal disease. Am J Kidney Dis 27(1):1–25CrossRef
14.
Zurück zum Zitat Longenecker JC, Coresh J, Marcovina SM, Powe NR, Levey AS, Giaculli F, Fink NE, Klag MJ (2003) Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 42(1):108–116CrossRef Longenecker JC, Coresh J, Marcovina SM, Powe NR, Levey AS, Giaculli F, Fink NE, Klag MJ (2003) Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis 42(1):108–116CrossRef
15.
Zurück zum Zitat Kollerits B, Drechsler C, Krane V, Lamina C, Marz W, Dieplinger H, Ritz E, Wanner C, Kronenberg F, German D, Dialysis Study I (2016) Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrol Dial Transpl 31(11):1901–1908. https://doi.org/10.1093/ndt/gfv428 CrossRef Kollerits B, Drechsler C, Krane V, Lamina C, Marz W, Dieplinger H, Ritz E, Wanner C, Kronenberg F, German D, Dialysis Study I (2016) Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrol Dial Transpl 31(11):1901–1908. https://​doi.​org/​10.​1093/​ndt/​gfv428 CrossRef
17.
Zurück zum Zitat Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol JASN 10(5):1027–1036PubMed Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol JASN 10(5):1027–1036PubMed
18.
Zurück zum Zitat Kaysen GA (2007) Hyperlipidemia in chronic kidney disease. Int J Artif Organs 30(11):987–992CrossRef Kaysen GA (2007) Hyperlipidemia in chronic kidney disease. Int J Artif Organs 30(11):987–992CrossRef
20.
Zurück zum Zitat Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, Group ESCSD (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272 CrossRefPubMed Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT, Group ESCSD (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058. https://​doi.​org/​10.​1093/​eurheartj/​ehw272 CrossRefPubMed
22.
Zurück zum Zitat Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S (1999) Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl 71:S242–S244CrossRef Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S (1999) Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl 71:S242–S244CrossRef
24.
Zurück zum Zitat Koda Y, Nishi S, Suzuki M, Hirasawa Y (1999) Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 71:S251–S253CrossRef Koda Y, Nishi S, Suzuki M, Hirasawa Y (1999) Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 71:S251–S253CrossRef
28.
Zurück zum Zitat Kronenberg F, Trenkwalder E, Sturm W, Kathrein H, Konig P, Neyer U, Grochenig E, Utermann G, Dieplinger H (1997) LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients. Clin Genet 52(5):377–386CrossRef Kronenberg F, Trenkwalder E, Sturm W, Kathrein H, Konig P, Neyer U, Grochenig E, Utermann G, Dieplinger H (1997) LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients. Clin Genet 52(5):377–386CrossRef
30.
Zurück zum Zitat Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F (1997) Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol JASN 8(12):1889–1898PubMed Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F (1997) Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol JASN 8(12):1889–1898PubMed
32.
Zurück zum Zitat Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395–1407. https://doi.org/10.1056/nejmoa0810177 CrossRefPubMed Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395–1407. https://​doi.​org/​10.​1056/​nejmoa0810177 CrossRefPubMed
34.
Zurück zum Zitat Kotani K, Banach M (2017) Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. J Thorac Dis 9(1):E78–E82CrossRef Kotani K, Banach M (2017) Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. J Thorac Dis 9(1):E78–E82CrossRef
36.
Zurück zum Zitat Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057):2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1 CrossRefPubMed Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057):2239–2253. https://​doi.​org/​10.​1016/​S0140-6736(16)31009-1 CrossRefPubMed
39.
Zurück zum Zitat Liberopoulos E, Siamopoulos K, Elisaf M (2004) Apolipoprotein E and renal disease. Am J Kidney Dis 43(2):223–233CrossRef Liberopoulos E, Siamopoulos K, Elisaf M (2004) Apolipoprotein E and renal disease. Am J Kidney Dis 43(2):223–233CrossRef
41.
Zurück zum Zitat Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J, Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ (1999) Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 100(6):608–613CrossRef Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J, Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ (1999) Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 100(6):608–613CrossRef
42.
Zurück zum Zitat Imura T, Kimura H, Gejyo F (1999) Apolipoprotein E phenotypes in hemodialysis patients. Kidney Int Suppl 71:S245–S247CrossRef Imura T, Kimura H, Gejyo F (1999) Apolipoprotein E phenotypes in hemodialysis patients. Kidney Int Suppl 71:S245–S247CrossRef
46.
Zurück zum Zitat Olmer M, Renucci JE, Planells R, Bouchouareb D, Purgus R (1997) Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transpl 12(4):691–693CrossRef Olmer M, Renucci JE, Planells R, Bouchouareb D, Purgus R (1997) Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transpl 12(4):691–693CrossRef
47.
Zurück zum Zitat Choi KH, Song HY, Shin SK, Noh H, Kang SW, Kim JH, Lee HY, Han DS (1999) Influence of apolipoprotein E genotype on lipid and lipoprotein levels in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial Conf Perit Dial 15:243–246 Choi KH, Song HY, Shin SK, Noh H, Kang SW, Kim JH, Lee HY, Han DS (1999) Influence of apolipoprotein E genotype on lipid and lipoprotein levels in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial Conf Perit Dial 15:243–246
52.
Zurück zum Zitat Lim PS, Liu CS, Hong CJ, Wei YH (1997) Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients. Nephrol Dial Transpl 12(9):1916–1920CrossRef Lim PS, Liu CS, Hong CJ, Wei YH (1997) Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients. Nephrol Dial Transpl 12(9):1916–1920CrossRef
57.
Zurück zum Zitat Kirmizis D, Koutoupa E, Tsiandoulas A, Valtopoulou A, Niavis G, Markou P, Barboutis K (2007) Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomark Insights 1:185–192PubMedPubMedCentral Kirmizis D, Koutoupa E, Tsiandoulas A, Valtopoulou A, Niavis G, Markou P, Barboutis K (2007) Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. Biomark Insights 1:185–192PubMedPubMedCentral
60.
63.
Zurück zum Zitat Bevc S, Hojs R, Ekart R, Hojs-Fabjan T (2006) Atherosclerosis in hemodialysis patients: traditional and nontraditional risk factors. Acta dermatovenerologica Alpina, Pannonica, et Adriatica 15(4):151–157PubMed Bevc S, Hojs R, Ekart R, Hojs-Fabjan T (2006) Atherosclerosis in hemodialysis patients: traditional and nontraditional risk factors. Acta dermatovenerologica Alpina, Pannonica, et Adriatica 15(4):151–157PubMed
Metadaten
Titel
A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives
verfasst von
Cristiana Vlad
Alexandru Burlacu
Laura Florea
Bogdan Artene
Silvia Badarau
Andreea Covic
Carina Ureche
Dragos Scripcariu
Liliana Foia
Adrian Covic
Publikationsdatum
22.05.2019
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 7/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02170-w

Weitere Artikel der Ausgabe 7/2019

International Urology and Nephrology 7/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.